Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04511871
Recruitment Status : Recruiting
First Posted : August 13, 2020
Last Update Posted : May 6, 2022
Shanghai Zhongshan Hospital
Information provided by (Responsible Party):
Shanghai PerHum Therapeutics Co., Ltd.

Brief Summary:
This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Gastric Cancer Breast Cancer Ovarian Cancer Sarcoma Biological: CCT303-406 Phase 1

Detailed Description:

This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT303-406 cells in adult subjects with HER2 positive relapsed or refractory stage IV metastatic solid tumors.

Subjects that meet inclusion criteria with positive biopsy HER2 (IHC 3+ in ≥50% tumor cells) will receive CCT303-406 according to the 3+3 dose escalation design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Actual Study Start Date : July 9, 2020
Estimated Primary Completion Date : October 29, 2022
Estimated Study Completion Date : October 29, 2023

Arm Intervention/treatment
Experimental: CCT303-406

To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CCT303-406 cell therapy in patients with HER2-positive (IHC 3+ in ≥50% tumor cells) relapsed or refractory solid tumors.

Dose cohorts:

  • Dose 1: 3x10^5 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
  • Dose 2: 1x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
  • Dose 3: 3x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
  • Dose 4: 1x10^7 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
Biological: CCT303-406
Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.

Primary Outcome Measures :
  1. MTD: to determine the maximum tolerated dose of CCT303-406 [ Time Frame: 28 days following infusion ]
    To assess the DLT (dose limiting toxicities) attributed to CCT303-406 per cohort and determine the RP2D (recommended phase 2 dose).

Secondary Outcome Measures :
  1. ORR (overall response rate): Proportion of subjects with the best overall response (BOR) [ Time Frame: Up to 52 weeks ]
    Best overall response (BOR) of subjects with PR (partial response) and CR (complete response) as determined by local investigator using RECIST 1.1

  2. 12 month survival rate [ Time Frame: Up to 52 weeks ]
    The proportion of living subjects within 52 weeks of infusion

  3. DCR: Disease control rate [ Time Frame: Up to 52 weeks ]
    The proportion of subjects with CR (complete response), PR (partial response) or SD (stable disease lasting over 6 months) as determined by local investigator using RECIST 1.1.

  4. DOR: Duration of reponse [ Time Frame: Up to 52 weeks ]
    The duration of time from record of response to first progression of disease as determined by RECIST 1.1 or death date not relevant to disease progression

  5. PFS: Progression free survival [ Time Frame: Up to 52 weeks ]
    The time of disease progression by RECIST 1.1 or death since cell infusion

  6. AE: Adverse Events [ Time Frame: Up to 52 weeks ]
    The incidence, severity and duration of AE, TEAE and SAE as determined by NCI-CTCAE v5.0

  7. The expansion over time of genetically modified CCT303-406 cells in the peripheral blood as determined by QPCR (copies/ug gDNA) [ Time Frame: Up to 52 weeks ]
    PK: Pharmacokinetics

  8. The persistence over time of genetically modified CCT303-406 cells in the peripheral blood as determined by Flow Cytometry (% CAR + cells) [ Time Frame: Up to 52 weeks ]
    PK: Pharmacokinetics

Other Outcome Measures:
  1. Exploration of target-PK correlation [ Time Frame: Up to 52 weeks ]
    The correlation between levels of HER2 expression and CCT303-406 PK by QPCR.

  2. Exploration of target-efficacy correlation [ Time Frame: Up to 52 weeks ]
    The correlation between levels of HER2 expression and DCR and DOR

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with willingness to be in the study and follow all study procedures, and capable of providing informed consent
  2. Male or female aged 18-70 years
  3. Patients with stage IV (according to the 8th edition of AJCC) advanced solid tumor malignancies that have failed standard treatment of relapsed or difficult-to-treat solid tumors confirmed by histology or cytology
  4. At least one measurable lesion, i.e. the length of non-lymph node lesions examined according to CT cross-sectional scanning or magnetic resonance imaging (MRI), or the short diameter of the lymph node lesions is ≥15 mm according to RECIST 1.1
  5. Tumors with HER2 IHC 3+ in≥50% of all tumor cells as determined by IHC according to the Breast Cancer HER2 Testing (2019 edition) and the Gastric Cancer HER2 Testing (2016 edition); For HER2 IHC 3+ tumors other than gastric and breast cancers, FISH is required to confirm HER2 expression; For relapsed patients after HER2-targeted therapies, biopsy and IHC are required to confirm HER2 expression per enrollment criteria.
  6. ECOG Performance Status 0-1
  7. Expected survival greater than 12 weeks
  8. Adequate organ and hematopoietic system functions to meet the following requirements:

    • Hemoglobin (HGB) s 90 g/L, no blood transfusions within two weeks;
    • White blood cell (WBC) count≥2.5×109/L
    • Absolute Neutrophil Count (ANC) ≥1.5 x 109/L
    • Platelet (PLT) count ≥80-109/L
    • Total bilirubin (TBIL) ≤3.0ng/dL or ≤5 ULN
    • ALT and AST ≤5 ULN; for liver metastasis, ALT and AST ≤5 ULN
    • Creatinine (Cr) ≤1.5 x ULN; or creatinine removal rate (CrCl) ≥50 mL/min
  9. LVEF≥50%
  10. Serum troponin T <0.03 ng/mL
  11. PT: INR < 1.7 or extended PT to normal value < 4s
  12. Normal language, recognition and consciousness assessed by investigator during screening phase
  13. Capable of receiving treatment and follow-up, including treatment in the clinical center;
  14. Female subjects of childbearing age must take acceptable measures to minimize the likelihood of pregnancy during the trial. The results of serum or urine pregnancy test must be negative
  15. Female subjects must not be in the lactation period.

Exclusion Criteria:

  1. Females with pregnancy or in lactation period
  2. Patients with active hepatitis B, or active hepatitis C
  3. HIV positive
  4. Other active infections of clinical significance
  5. Patients receiving in situ surgery within 3 months
  6. Patients with the following previous or accompanying diseases:

    • Patients diagnosed as severe autoimmune diseases that require long term (more than 2 months) treatment with systemic immunosuppressants (steroids), or diseases with immune-mediated symptoms, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis

  7. Patients with ≥Grade 2 peripheral neuronal diseases (according to NCI-CTCAE v5.0)
  8. Patients with any mental illness, including dementia, mental changes, which may cause difficulties understanding the informed consent and related questionnaires
  9. Patients with serious uncontrollable diseases, which may interfere with the therapies in this study
  10. Patients with other active malignancies in the past 5 years excluding those with completely cured basal or squamous skin cancers, superficial bladder cancers or primary breast cancers without need of follow-up treatment
  11. Patients receiving systemic steroids or steroid inhalants
  12. Patients who have received tumor immunotherapy (including monoclonal antibody or cell therapy) in the past 4 weeks
  13. Patients allergic to immunotherapies or related drugs
  14. Patients with metastatic lesions in meninges or central nervous system, or clear evidence of central nervous system diseases with continous significant symptoms in the last 6 months
  15. Patients with NYHA class II heart failure, or hypertension incontrollable by standard care, or medical history of myocarditis, or heart attack within a year
  16. Patients who have received or are going to receive organ transplantation
  17. Patients with active bleeding
  18. Patients with incontrollable pleural or abdominal fluid that needs clinical treatment or intervention
  19. Patients having undergone major surgery within 4 weeks or have not fully recovered from prior surgery
  20. Patients that have received radiotherapy within 4 weeks, excluding those who received local irradiation for the peripheral bone metastatic lesions for more than 2 weeks, and recovered from all acute toxicities of radiotherapy
  21. Patients that have received anthracyclines within 8 weeks
  22. Patients as determined by the investigators to be inappropriate for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04511871

Layout table for location information
China, Shanghai
Zhongshan Hospital Affiliated to Fudan University Recruiting
Shanghai, Shanghai, China, 200032
Contact: Yuhong Zhou, M.D.    +86-21-64041990 ext 2968   
Contact: Wei Zhang, Ph.D.    +86-18321825338   
Sponsors and Collaborators
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital
Layout table for additonal information
Responsible Party: Shanghai PerHum Therapeutics Co., Ltd. Identifier: NCT04511871    
Other Study ID Numbers: CCT303-406-mST01
First Posted: August 13, 2020    Key Record Dates
Last Update Posted: May 6, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shanghai PerHum Therapeutics Co., Ltd.:
Solid tumors